DO-BO

Is Healthcare just a business in the US, Aymeric Chaupin?

In this captivating episode of MAP, the Market Access Podcast, we welcome Aymeric Chaupin, a seasoned expert in pricing and market access. Aymeric’s unique perspective, shaped by his deep understanding of both the American and European healthcare systems, sheds light on the complexities of healthcare reimbursement pathways in the US and their impact on the delivery of health services.

Join us as Aymeric unveils the challenges and opportunities within the US healthcare market. He emphasizes the importance of coding and understanding reimbursement pathways for effective market access and explores the broader implications for patient care and the healthcare system as a whole.

This episode is a treasure trove of insights for startups and companies looking to navigate the US healthcare landscape. Aymeric shares practical advice on entering the market, from partnering with pharmaceutical giants to engaging with the FDA early in the clinical trial process. He stresses the necessity of having a clear strategy and representation in the US to negotiate coverage and formulary placement, ensuring commercial success in this pivotal market.

Despite the hurdles, the US remains a key player in the global pharmaceutical and medical device industry, accounting for a significant portion of global revenue.

Tune in for an enlightening discussion that navigates the intricacies of the US healthcare system, providing valuable lessons and strategies for companies aspiring to make their mark in this challenging yet rewarding market.

Related

In this episode, Stefan Walzer talks with experienced Market Access manager Helmut Butscher about concrete AI applications across the full Market Access value chain. They explore how AI accelerates systematic literature reviews, unlocks real‑world evidence from complex data sources, supports HTA dossier preparation, and enables smarter decisions on pricing, reimbursement and global launch sequencing. They […]

In this thought‑provoking Market Access Podcast episode, host Stefan Walzer sits down with Omar Ali – Head of Payers at Vipora, former NICE advisor, and one of the sharpest minds in drug pricing and innovative contracting to unpack where drug pricing and reimbursement are really heading.  They explore why cost‑effectiveness thresholds are making market access […]

In this Market Access Podcast episode, Dr. Stefan Walzer sits down with Prof. Zanfania Ademi, a health economist at Monash University, to explore how Australia’s healthcare system is tackling key issues in market access and health technology assessment. Discover how Australia blends international approaches and new methods being developed by Zanfina and her team like […]